170 related articles for article (PubMed ID: 37877812)
1. Correction to: Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Inflamm Bowel Dis; 2023 Dec; 29(12):2011-2012. PubMed ID: 37877812
[No Abstract] [Full Text] [Related]
2. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis.
Lee MJ; Parker CE; Taylor SR; Guizzetti L; Feagan BG; Lobo AJ; Jairath V
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1879-1892. PubMed ID: 29374617
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.
Attauabi M; Burisch J; Seidelin JB
Scand J Gastroenterol; 2021 Jan; 56(1):53-58. PubMed ID: 33264569
[TBL] [Abstract][Full Text] [Related]
6. Enteral nutritional therapy for inducing remission of Crohn's disease.
Zachos M; Tondeur M; Griffiths AM
Cochrane Database Syst Rev; 2001; (3):CD000542. PubMed ID: 11686966
[TBL] [Abstract][Full Text] [Related]
7. Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future.
Caron B; D'Amico F; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Aug; 15(8):1387-1398. PubMed ID: 33550374
[TBL] [Abstract][Full Text] [Related]
8. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
Barberio B; Gracie DJ; Black CJ; Ford AC
Gut; 2023 Feb; 72(2):264-274. PubMed ID: 35907636
[TBL] [Abstract][Full Text] [Related]
10. Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis.
Roseira J; Santiago M; Estevinho MM; Moreira P; Alves C; Danese S; Peyrin-Biroulet L; Dignass A; Feakins R; Magro F
Inflamm Bowel Dis; 2023 Aug; 29(8):1231-1243. PubMed ID: 36250778
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
13. Enteral nutritional therapy for induction of remission in Crohn's disease.
Zachos M; Tondeur M; Griffiths AM
Cochrane Database Syst Rev; 2007 Jan; (1):CD000542. PubMed ID: 17253452
[TBL] [Abstract][Full Text] [Related]
14. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
15. Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.
Sharma T; Ma C; Sedano R; Hanzel J; McDonald C; Hogan M; Kochhar GS; Narula N; Peyrin-Biroulet L; Danese S; MacDonald JK; Jairath V
J Crohns Colitis; 2023 Apr; 17(4):644-658. PubMed ID: 36271904
[TBL] [Abstract][Full Text] [Related]
16. Fistula response to methotrexate in Crohn's disease: a case series.
Mahadevan U; Marion JF; Present DH
Aliment Pharmacol Ther; 2003 Nov; 18(10):1003-8. PubMed ID: 14616166
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series.
Kouklakis G; Efremidou EI; Zezos P; Liratzopoulos N; Souftas VD; Gatopoulou A; Simopoulos K; Manolas KJ
J Med Case Rep; 2011 Mar; 5():109. PubMed ID: 21418588
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
[TBL] [Abstract][Full Text] [Related]
19. Transcending conventional therapies: the role of biologic and other novel therapies.
Sandborn WJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
